# Neogenomics Inc: financial statements, quarterly

NEO · Nasdaq · CIK 1077183 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/neo.md) · [Financials](/companies/neo/financials.md) · [Filings](/companies/neo/filings.md) · [Insiders](/companies/neo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/neo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [152](/filings/0001077183-24-000157.md) | [156 d](/filings/0001077183-26-000010.md) | [156](/filings/0001077183-25-000076.md) | [165](/filings/0001077183-25-000154.md) | [168](/filings/0001077183-25-000175.md) | [172 d](/filings/0001077183-26-000010.md) | [168](/filings/0001077183-26-000023.md) | [181](/filings/0001077183-26-000059.md) | [188](/filings/0001077183-25-000175.md) | [190 d](/filings/0001077183-26-000010.md) | [187](/filings/0001077183-26-000023.md) | [202](/filings/0001077183-26-000059.md) |
| Cost of revenue | $m | [89.6](/filings/0001077183-24-000157.md) | [88.0 d](/filings/0001077183-26-000010.md) | [90.8](/filings/0001077183-25-000076.md) | [92.0](/filings/0001077183-25-000154.md) | [92.9](/filings/0001077183-25-000175.md) | [94.7 d](/filings/0001077183-26-000010.md) | [94.8](/filings/0001077183-26-000023.md) | [104](/filings/0001077183-26-000059.md) | [107](/filings/0001077183-25-000175.md) | [107 d](/filings/0001077183-26-000010.md) | [106](/filings/0001077183-26-000023.md) | [110](/filings/0001077183-26-000059.md) |
| Gross profit | $m | [62.3](/filings/0001077183-24-000157.md) | [67.6 d](/filings/0001077183-26-000010.md) | [65.5](/filings/0001077183-25-000076.md) | [72.5](/filings/0001077183-25-000154.md) | [74.9](/filings/0001077183-25-000175.md) | [77.3 d](/filings/0001077183-26-000010.md) | [73.2](/filings/0001077183-26-000023.md) | [77.3](/filings/0001077183-26-000059.md) | [80.4](/filings/0001077183-25-000175.md) | [83.3 d](/filings/0001077183-26-000010.md) | [80.9](/filings/0001077183-26-000023.md) | [91.9](/filings/0001077183-26-000059.md) |
| Research and development | $m | [5.3](/filings/0001077183-24-000157.md) | [7.1 d](/filings/0001077183-26-000010.md) | [7.6](/filings/0001077183-25-000076.md) | [7.9](/filings/0001077183-25-000154.md) | [7.7](/filings/0001077183-25-000175.md) | [8.0 d](/filings/0001077183-26-000010.md) | [10.2](/filings/0001077183-26-000023.md) | [9.0](/filings/0001077183-26-000059.md) | [8.7](/filings/0001077183-25-000175.md) | [9.2 d](/filings/0001077183-26-000010.md) | [9.5](/filings/0001077183-26-000023.md) | [10.8](/filings/0001077183-26-000059.md) |
| Operating income | $m | [(24.2)](/filings/0001077183-24-000157.md) | [(18.6) d](/filings/0001077183-26-000010.md) | [(30.6)](/filings/0001077183-25-000076.md) | [(21.9)](/filings/0001077183-25-000154.md) | [(21.2)](/filings/0001077183-25-000175.md) | [(18.4) d](/filings/0001077183-26-000010.md) | [(27.8)](/filings/0001077183-26-000023.md) | [(47.6)](/filings/0001077183-26-000059.md) | [(27.0)](/filings/0001077183-25-000175.md) | [(13.4) d](/filings/0001077183-26-000010.md) | [(18.2)](/filings/0001077183-26-000023.md) | [(9.8)](/filings/0001077183-26-000059.md) |
| Interest expense | $m | [(2.8)](/filings/0001077183-23-000138.md) | [13.7 d](/filings/0001077183-24-000011.md) | [1.7](/filings/0001077183-24-000054.md) | [1.7](/filings/0001077183-25-000154.md) | [1.6](/filings/0001077183-25-000175.md) | [1.6 d](/filings/0001077183-26-000010.md) | [1.6](/filings/0001077183-26-000023.md) | [0.9](/filings/0001077183-26-000059.md) | [0.6](/filings/0001077183-25-000175.md) | [0.6 d](/filings/0001077183-26-000010.md) | [0.6](/filings/0001077183-26-000023.md) | [0.8](/filings/0001077183-26-000059.md) |
| Income tax | $m | [(2.9)](/filings/0001077183-24-000157.md) | [(1.0) d](/filings/0001077183-26-000010.md) | [(0.6)](/filings/0001077183-25-000076.md) | [(0.4)](/filings/0001077183-25-000154.md) | [(0.2)](/filings/0001077183-25-000175.md) | [(0.8) d](/filings/0001077183-26-000010.md) | [0.3](/filings/0001077183-26-000023.md) | [(0.7)](/filings/0001077183-26-000059.md) | [0.7](/filings/0001077183-25-000175.md) | [(2.5) d](/filings/0001077183-26-000010.md) | [(0.5)](/filings/0001077183-26-000023.md) | [(0.4)](/filings/0001077183-26-000059.md) |
| Net income | $m | [(18.5)](/filings/0001077183-24-000157.md) | [(14.3) d](/filings/0001077183-26-000010.md) | [(27.1)](/filings/0001077183-25-000175.md) | [(18.6)](/filings/0001077183-25-000175.md) | [(17.7)](/filings/0001077183-25-000175.md) | [(15.3) d](/filings/0001077183-26-000010.md) | [(25.9)](/filings/0001077183-26-000059.md) | [(45.1)](/filings/0001077183-26-000059.md) | [(27.1)](/filings/0001077183-25-000175.md) | [(9.9) d](/filings/0001077183-26-000010.md) | [(17.1)](/filings/0001077183-26-000059.md) | [2.2](/filings/0001077183-26-000059.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [306](/filings/0001077183-23-000138.md) | [342](/filings/0001077183-25-000028.md) | [332](/filings/0001077183-24-000054.md) | [355](/filings/0001077183-24-000109.md) | [362](/filings/0001077183-24-000157.md) | [367](/filings/0001077183-26-000010.md) | [346](/filings/0001077183-25-000076.md) | [155](/filings/0001077183-25-000154.md) | [164](/filings/0001077183-25-000175.md) | [160](/filings/0001077183-26-000059.md) | [146](/filings/0001077183-26-000023.md) | [146](/filings/0001077183-26-000059.md) |
| Current assets | $m | [587](/filings/0001077183-23-000138.md) | [597](/filings/0001077183-25-000028.md) | [574](/filings/0001077183-24-000054.md) | [584](/filings/0001077183-24-000109.md) | [590](/filings/0001077183-24-000157.md) | [596](/filings/0001077183-26-000010.md) | [574](/filings/0001077183-25-000076.md) | [393](/filings/0001077183-25-000154.md) | [382](/filings/0001077183-25-000175.md) | [376](/filings/0001077183-26-000059.md) | [374](/filings/0001077183-26-000023.md) | [381](/filings/0001077183-26-000059.md) |
| Total assets | $m | [1,678](/filings/0001077183-23-000138.md) | [1,681](/filings/0001077183-25-000028.md) | [1,640](/filings/0001077183-24-000054.md) | [1,643](/filings/0001077183-24-000109.md) | [1,641](/filings/0001077183-24-000157.md) | [1,638](/filings/0001077183-26-000010.md) | [1,601](/filings/0001077183-25-000076.md) | [1,394](/filings/0001077183-25-000154.md) | [1,375](/filings/0001077183-25-000175.md) | [1,360](/filings/0001077183-26-000059.md) | [1,347](/filings/0001077183-26-000023.md) | [1,352](/filings/0001077183-26-000059.md) |
| Current liabilities | $m | [92.9](/filings/0001077183-23-000138.md) | [96.3](/filings/0001077183-25-000028.md) | [76.7](/filings/0001077183-24-000054.md) | [290](/filings/0001077183-24-000109.md) | [296](/filings/0001077183-24-000157.md) | [301](/filings/0001077183-26-000010.md) | [280](/filings/0001077183-25-000076.md) | [100](/filings/0001077183-25-000154.md) | [97.9](/filings/0001077183-25-000175.md) | [88.3](/filings/0001077183-26-000059.md) | [84.6](/filings/0001077183-26-000023.md) | [106](/filings/0001077183-26-000059.md) |
| Total liabilities | $m | [731](/filings/0001077183-23-000138.md) | [740](/filings/0001077183-25-000028.md) | [717](/filings/0001077183-24-000054.md) | [727](/filings/0001077183-24-000109.md) | [733](/filings/0001077183-24-000157.md) | [736](/filings/0001077183-26-000010.md) | [713](/filings/0001077183-25-000076.md) | [540](/filings/0001077183-25-000154.md) | [536](/filings/0001077183-25-000175.md) | [523](/filings/0001077183-26-000059.md) | [518](/filings/0001077183-26-000023.md) | [567](/filings/0001077183-26-000059.md) |
| Long-term debt | $m | not reported | [538](/filings/0001077183-25-000028.md) | not reported | not reported | not reported | [340](/filings/0001077183-26-000010.md) | not reported | not reported | not reported | [342](/filings/0001077183-26-000059.md) | not reported | [374](/filings/0001077183-26-000059.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [201](/filings/0001077183-25-000028.md) | not reported | not reported | not reported | [0.0](/filings/0001077183-26-000010.md) | not reported | not reported |
| Shareholders' equity | $m | [947](/filings/0001077183-24-000157.md) | [942](/filings/0001077183-26-000010.md) | [923](/filings/0001077183-25-000175.md) | [916](/filings/0001077183-25-000175.md) | [908](/filings/0001077183-25-000175.md) | [902](/filings/0001077183-26-000059.md) | [888](/filings/0001077183-26-000059.md) | [854](/filings/0001077183-26-000059.md) | [838](/filings/0001077183-25-000175.md) | [837](/filings/0001077183-26-000059.md) | [829](/filings/0001077183-26-000059.md) | [786](/filings/0001077183-26-000059.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.5) d](/filings/0001077183-24-000157.md) | [17.8 d](/filings/0001077183-26-000010.md) | [(25.9)](/filings/0001077183-25-000076.md) | [13.9 d](/filings/0001077183-25-000154.md) | [9.2 d](/filings/0001077183-25-000175.md) | [9.8 d](/filings/0001077183-26-000010.md) | [(25.3)](/filings/0001077183-26-000023.md) | [20.3 d](/filings/0001077183-26-000059.md) | [8.9 d](/filings/0001077183-25-000175.md) | [1.3 d](/filings/0001077183-26-000010.md) | [(8.1)](/filings/0001077183-26-000023.md) | [20.0 d](/filings/0001077183-26-000059.md) |
| Capital expenditure | $m | [4.3 d](/filings/0001077183-24-000157.md) | [7.1 d](/filings/0001077183-26-000010.md) | [5.6](/filings/0001077183-25-000076.md) | [13.1 d](/filings/0001077183-25-000154.md) | [10.8 d](/filings/0001077183-25-000175.md) | [11.6 d](/filings/0001077183-26-000010.md) | [4.5](/filings/0001077183-26-000023.md) | [6.3 d](/filings/0001077183-26-000059.md) | [8.3 d](/filings/0001077183-25-000175.md) | [7.9 d](/filings/0001077183-26-000010.md) | [5.0](/filings/0001077183-26-000023.md) | [8.2 d](/filings/0001077183-26-000059.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [124](/filings/0001077183-23-000138.md) | [125](/filings/0001077183-24-000054.md) | [125](/filings/0001077183-24-000109.md) | [126](/filings/0001077183-24-000157.md) | [126](/filings/0001077183-25-000076.md) | [126](/filings/0001077183-25-000154.md) | [127](/filings/0001077183-25-000175.md) | [127](/filings/0001077183-26-000023.md) | [128](/filings/0001077183-26-000059.md) | [128](/filings/0001077183-25-000175.md) | [129](/filings/0001077183-26-000023.md) | [131](/filings/0001077183-26-000059.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 128,475,440 at 2026-07-24, from the cover of the [10-Q filed 2026-07-28](/filings/0001077183-26-000059.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.